At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
MORAb-009 (Amatuximab) +2 moredrug
Likely dose
Pemetrexed 500 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
In Brief
A Phase 2 clinical trial evaluating MORAb-009 (Amatuximab), Pemetrexed, and 1 other intervention for Malignant Pleural Mesothelioma. Completed, enrolled 89 participants across 28 sites in 5 countries.
Detailed Summary
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Pleural Mesothelioma
CountriesCanada, Germany, Netherlands, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartDec 2008
Primary CompletionJun 2011
Study CompletionJan 2014
TodayJul 2026
First PostedAug 20, 2008
Enrollment StartDec 31, 2008
Primary CompletionJun 30, 2011
Study CompletionJan 10, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.9 years ago
Interventions
MORAb-009 (Amatuximab)drug
MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
Pemetrexeddrug
Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
Cisplatindrug
Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles